HER2 targeting in cancers is currently following two approaches: (i) targeted therapies using monoclonal antibodies preventing HER2 interaction, or (ii) tyrosine kinase inhibitors blocking phosphorylation of HER2, thereby inhibiting its downstream signaling activity [11,12]. This evidence concerns the gene ERBB2 and cancer.